Lexaria Bioscience Augments Business Development and Awarded New Patents

Kelowna, British Columbia — October 9, 2025 — Leads & Copy — Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) is augmenting its business development activities by hiring a global life science business development advisory firm to identify and pursue additional collaborative business opportunities. The company also announced it has been awarded four new patents.

Lexaria is validating the applicability of its patented DehydraTECH technology across a number of sectors within the pharmaceutical industry. Lexaria’s R&D validation programs have already identified several pharmaceutical areas of interest including, but not limited to: treatments for diabetes control and weight loss, hypertension, seizure disorders, anti-viral applications and hormone replacement.

The resources permitting this expansion of strategic outreach, and key supportive R&D related thereto, have been made available through Lexaria’s recently completed equity financing which yielded gross proceeds of $4.0 million. The additional capital was required in order to advance and execute plans for important supportive new R&D expansion activities into 2026.

Lexaria is now able to advance its business development and R&D programs through the winter and into the first half of calendar 2026.

The new patents are summarized as follows:

Issued
Patent #
Patent Certificate Grant Date
Patent
Family
AU 2024202475
July 24, 2025
#24 Compositions and Methods for Treating
Epilepsy
US 12,397,042
August 26, 2025
#27 Compositions and Methods for Treating
Diabetes
EP 3858364
September 17, 2025
#1 Food and Beverage Compositions Infused With
Lipophilic Active Agents and Methods of Use Thereof
AU 2023200736
October 2, 2025
#18 Compositions and Methods for Enhanced Delivery of
Antiviral Agents

These initiatives are being pursued to give Lexaria additional “shots on goal” and opportunities to build shareholder value.

Investor Contact:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext. 202

Source: Lexaria Bioscience Corp.